8-K current report · filed Aug 10, 2026

Perspective Therapeutics, Inc. (CATX) 8-K Current Report: August 10, 2026

Item EX-99.1Item EX-99.2Item 2.02Item 8.01CATX overview

Short answer

Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on August 10, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Q2 2026 financial results and recent business highlights announced for quarter ended June 30, 2026.

Perspective Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results and recent business highlights announced for quarter ended June 30, 2026
  • Full results and operating updates contained in Exhibit 99.1 press release

Item 8.01 · Other Events

  • Updated corporate presentation posted August 10, 2026, signaling refreshed company messaging for investors
  • Exhibit 99.2 contains the substantive presentation, including any updated business or pipeline information

Item EX-99.1 · Exhibit EX-99.1

  • Cash, equivalents and short-term investments $237M at June 30, 2026, funding planned milestones and operations into late 2027
  • VMT-α-NET Phase 3 site activation targeted around year-end 2026, pending regulatory alignment and protocol finalization
  • VMT-α-NET data presentation scheduled at ESMO October 23, offering a near-term clinical catalyst
  • Second-quarter R&D expense rose to $21.5M from $16.6M, reflecting continued pipeline and manufacturing investment
  • Net loss widened to $26.8M from $21.5M, while loss per share improved to $0.22 from $0.29 on higher share count

Item EX-99.2 · Exhibit EX-99.2

  • Investor presentation highlights Perspective’s pipeline of ²¹²Pb radiopharmaceuticals targeting neuroendocrine tumors, melanoma and broader solid tumors
  • VMT-α-NET Phase 1/2a data feature responses deepening over time and durable disease control across dose levels
  • VMT-α-NET treated 68 patients, supporting potential registration-study planning at the current dose level
  • VMT01 and PSV359 showed preliminary antitumor activity and tumor-retention potential, but remain early-stage programs
  • Integrated isotope production and regional manufacturing aim to support direct-to-hospital delivery and scalable product supply

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Perspective Therapeutics, Inc. 8-K filings

Get the next CATX 8-K as it lands

Follow CATX for push alerts, or ask the research agent what this filing means.